Cybantage has been in the post-breach environment — claim denials, board proceedings, the personal financial exposure that follows when a GP holds a board seat and a portfolio company's claim is denied. We built the CCSF from that experience. The portfolio program applies it across every holding before those conversations happen.
The GP's relationship with portfolio cyber risk is not static. It changes at three specific points — and the cost of not addressing it differs at each one.
Before price is set and representations and warranties are negotiated, you need to know whether the target's cyber insurance coverage actually responds — and whether there are unreviewed policy exclusions that create uninsured liability at closing.
Within 90 days of close, every portfolio company receives a CISI baseline. Critical findings trigger Stage 2A/2B. Domain 10 flags trigger an immediate policy review. The Operating Partner receives a consolidated defensibility scorecard across all holdings.
18–36 months before target close, the portfolio company's cyber posture becomes a buy-side diligence item. A company with a current Privileged Review Record, annual CISI re-scores, and a reviewed Domain 10 position wins on diligence against one that doesn't.
Every portfolio company in healthcare + MedTech, financial services + FinTech, and manufacturing faces both dimensions. Most security programs address only one. The second requires a policy review — and it has been in every regulated sector policy since March 2023.
Addressable through security investment and governance. This is what your portfolio companies' MSSPs and compliance programs address. Most security programs are here. Most forensic investigators find gaps here.
Not addressable through security investment. Present in every regulated sector policy following the Lloyd's 2023 mandate. No MSSP, compliance audit, or security program addresses this. Only a policy review does.
When a breach occurs at a portfolio company where you hold a board seat, regulators and opposing counsel ask what the board knew, when they knew it, and what they did about it. Cybantage has been present in those proceedings. The Privileged Review Record is the protected answer to those three questions — prepared before the breach, under attorney-client privilege, while there is still time to act. Executives and GPs who hold a current Record walk into board inquiries, regulatory examinations, and depositions in a fundamentally different posture than those who do not.
The CCSF applies identically to portfolio company engagements. The entry point and stage sequencing are determined by each company's CISI score and D10 status. The Operating Partner sees a consolidated view.
Every holding assessed within 90 days of close. Score, domain failures, and D10 flags determine the Stage 2 routing. $2,500 per company.
Triggered by score below 169 or any D10 flag. Maps governance gaps that create board-level liability. Recommend under privilege.
Domain 10 policy review with insurance counsel. Privileged Review Record. Board Package. The anchor product for GP board seat protection.
Confirms control state of acquisition target before price is set. Forensic-grade — the same standard the carrier's investigator applies.
Closes every gap found in Stages 1–3. Sustains the posture through every renewal cycle. Builds the exit diligence defense record.
31.3% of healthcare organizations that experienced a significant breach ceased to exist independently. The research is clear on why. The CCSF addresses the same variables the research identified as survivability determinants.
FTC Safeguards enforcement is active. DORA requirements are expanding. The compliance-to-forensic gap is structural in this sector — and the Lloyd's nation-state exclusion applies to the most likely threat actor class.
OT ransomware is up 87% since 2022. Business interruption policies frequently exclude non-malicious correlated outages — the CrowdStrike scenario. $1.4M per day when production stops is the industry average for OT downtime.
The 30-minute portfolio conversation draws on direct experience in claim denial proceedings — including the specific moment when a GP holding a board seat discovers that a portfolio company's coverage didn't respond. We'll cover your fund's vertical focus and portfolio composition, the specific Domain 10 exposure profile for your sector, how the CCSF program works at the portfolio level, and what the economics look like for your holding count.
Select a time that works for you.
Cybantage Portfolio Program / VC-PE Conversation · 30 minutes